Literature DB >> 19582894

Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats.

Dirk Lebrecht1, Ana C Venhoff, Janbernd Kirschner, Thorsten Wiech, Nils Venhoff, Ulrich A Walker.   

Abstract

OBJECTIVES: Tenofovir disoproxil fumarate (tenofovir DF) use has been associated with renal dysfunction and Fanconi syndrome. Tenofovir is taken up into renal tubules by anion transporters where high intracellular drug concentration may induce a functionally relevant depletion of mitochondrial DNA (mtDNA). We investigated if tenofovir may induce renal mtDNA depletion and respiratory chain dysfunction.
METHODS: Rats (n = 8) were gavaged daily with 100 mg x kg(-1) x d(-1) of tenofovir DF or didanosine. Kidneys and livers were examined after 8 weeks of treatment.
RESULTS: The tenofovir group had significantly lower body and kidney weights than rats exposed to water or didanosine. Proximal but not distal tubules were of increased diameter and contained small lipid droplets. Tubular mitochondria were enlarged, and their crystal architecture was disrupted. Tenofovir-exposed kidneys contained low mtDNA copy numbers and impaired expression of mtDNA-encoded cytochrome c oxidase (COX) I but not nucleus-encoded COX IV subunits. Histochemistry demonstrated low tubular COX and nicotinamide adenine dinucleotide dehydrogenase (NADH-DH) activities, whereas succinate dehydrogenase activity was preserved. COX activity was preserved in the glomeruli of tenofovir-exposed rats. Didanosine did not elicit renal effects but, unlike tenofovir, depleted mtDNA in liver (by 52%).
CONCLUSIONS: Tenofovir DF induces an organ-specific nephrotoxicity with mtDNA depletion and dysfunction of mtDNA-encoded respiratory chain subunits. The data do not support nephrotoxicity of didanosine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19582894     DOI: 10.1097/qai.0b013e3181a666eb

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  35 in total

1.  Polymorphisms in Fas gene is associated with HIV-related lipoatrophy in Thai patients.

Authors:  Sirirat Likanonsakul; Tippawan Rattanatham; Siriluk Feangvad; Sumonmal Uttayamakul; Wisit Prasithsirikul; Somkid Srisopha; Ravee Nitiyanontakij; Pimrapat Tengtrakulcharoen; Maciej Tarkowski; Agostino Riva; Emi E Nakayama; Tatsuo Shioda
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-20       Impact factor: 2.205

2.  Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.

Authors:  Andrés Duarte-Rojo; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

Review 3.  Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.

Authors:  Atefeh Jafari; Hossein Khalili; Simin Dashti-Khavidaki
Journal:  Eur J Clin Pharmacol       Date:  2014-06-25       Impact factor: 2.953

Review 4.  Update on tenofovir toxicity in the kidney.

Authors:  Andrew M Hall
Journal:  Pediatr Nephrol       Date:  2012-08-10       Impact factor: 3.714

Review 5.  Pharmacogenomics of antimicrobial agents.

Authors:  Ar Kar Aung; David W Haas; Todd Hulgan; Elizabeth J Phillips
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

6.  Tenofovir disoproxil fumarate: toxicity, toxicokinetics, and toxicogenomics analysis after 13 weeks of oral administration in mice.

Authors:  Hanna H Ng; Howard Stock; Linda Rausch; Deborah Bunin; Abraham Wang; Shirley Brill; Jason Gow; Jon C Mirsalis
Journal:  Int J Toxicol       Date:  2015-01-07       Impact factor: 2.032

Review 7.  HIV therapies and the kidney: some good, some not so good?

Authors:  Lene Ryom; Amanda Mocroft; Jens Lundgren
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

8.  Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.

Authors:  Lene Ryom; Amanda Mocroft; Ole Kirk; Signe W Worm; David A Kamara; Peter Reiss; Michael Ross; Christoph A Fux; Philippe Morlat; Olivier Moranne; Colette Smith; Jens D Lundgren
Journal:  J Infect Dis       Date:  2013-02-04       Impact factor: 5.226

9.  The Use of Cytochrome C Oxidase Enzyme Activity and Immunohistochemistry in Defining Mitochondrial Injury in Kidney Disease.

Authors:  Zsuzsanna K Zsengellér; Seymour Rosen
Journal:  J Histochem Cytochem       Date:  2016-09       Impact factor: 2.479

10.  Tenofovir-associated bone density loss.

Authors:  Iwen F Grigsby; Lan Pham; Louis M Mansky; Raj Gopalakrishnan; Kim C Mansky
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.